March 1st, 2011 -- Immune Response BioPharma on the Move Announces Plans to Develop Sepsicillin TM Antibiotic Treatment for Sepsis using BPI Bactericidal Permeability-Increasing Protein Formulation
Immune Response BioPharma, Fredericksburg, Virginia Today 3/1/2011 privately held announces intentions to develop Sepsicillin a drug for Sepsis using our BPI Bactericidal Permeability-Increasing Protein proprietary formulation. Immune Response BioPharma begins work on important life-saving drug Sepsicillin TM.
Today is a great day for the patients suffering from sepsis and their families by developing Sepsicillin TM this gives them hope of fighting off this terrible disease. Sepsis is an awful disease afflicting many people across the globe which has devastating implications for anyone who has this life threatening illness. Once the body goes into shock from bacterial infection it is almost impossible to halt the bug from causing serious internal organ failure. BPI Bactericidal Permeability-Increasing Protein proprietary formulation with our antibiotic combination will offer doctors and patients a strong drug to combat this life threatening disease.
“Developing Sepsicillin TM is the right thing to do for patients and their loved ones as it is critical for doctors to have new and powerful antibiotic tools at their disposal to fight off this awful disease. I personally have suffered a big loss from sepsis when my father went into shock once the bug defeated his immune system. Sepsicillin will help trigger an immune response by using BPI in combination with other antibiotics this will serve as a dynamic and powerful drug with broad spectrum capabilities to fight off sepsis shock. I will do what I can to help save lives from sepsis” Mr. Buswell Chief Operating Officer.
Immune Response BioPharma is a diversified biopharmaceutical company engaged in the process of developing lifesaving drugs and therapeutic vaccines in the auto-immune, infectious disease areas. The company has a deep pipeline of experimental drugs it plans to develop. Plans to raise capital is neither an offer nor solicitation for sale of securities. Safe Harbor disclosure. Immune Response BioPharma may be found on the world wide web at www.immuneresponsebiopharma.com
Media Contact Info Info@immuneresponsebiopharma.com
Mr. David Buswell Chief of Immune Response BioPharma @ (540)-760-0535
Mr. Buswell is a University of Mary Washington Business & Commerce Graduate in Fredericksburg, Va
